Ceva Animal Health invests in new 7,000 m² vaccine manufacturing facility to expand global production capacity

26-Nov-2024

Ceva animal health (Ceva) unveils its latest investment in European vaccine manufacturing, with the construction of a new facility in Hungary, expanding the capacity of Ceva Phylaxia. This development will establish a 7,000 m2 plant in Monor, Hungary withthe most advanced technologies,where Ceva will produce fermentation-based multicomponent inactivated vaccines for animals.

Ceva Animal Health (Ceva)

For over 20 years, Ceva has been a strong advocate for prevention through vaccination, heavily investing in preventive medicine to significantly improve the health of husbandries but also to fight zoonotic and emerging diseases, contributing to prepare for future pandemics.

Today, 54% of Ceva’s R&D budget is dedicated to vaccine development and the company already provides more than 50 vaccines to fight 19 zoonotic diseases.

With this investment, it will further strengthen its position, producing more than 8 billion doses of vaccines in this new manufacturing plant annually, on top of other animal health products.

“Building a new facility is always a significant milestone in the life of a company. In Hungary, we already benefit from a strong historical expertise with our Ceva Phylaxia campus. With the addition of this new production unit in Monor, we aim to create new synergies to advance preventive medicine. This project reflects our commitment to supporting farmers worldwide by developing tailored solutions to tackle emerging diseases and new variants. It embodies our ambition to build a promising future for our company, employees, and partners, both in Hungary and internationally, while strengthening our research and development capabilities.” says Marc Prikazsky, Chairman and CEO of Ceva Animal Health.

The new plant is scheduled to start operations at the end of 2026.

Other news from the department manufacturing

Most read news

More news from our other portals

Last viewed contents

Daiichi Sankyo's investments in cancer drugs are taking shape - From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany

Daiichi Sankyo's investments in cancer drugs are taking shape - From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany

Waldner: Ground-breaking for new powder coating plant

Waldner: Ground-breaking for new powder coating plant

Roche lays the foundation for the diagnostics production of the future in Germany - Investment of more than 600 million euros in a high-tech production center - Roche's largest single investment in Germany to date

Roche lays the foundation for the diagnostics production of the future in Germany - Investment of more than 600 million euros in a high-tech production center - Roche's largest single investment in Germany to date

ProBioGen expands protein and virus manufacturing to drive continued growth

ProBioGen expands protein and virus manufacturing to drive continued growth

Sensirion opens additional production building in Debrecen

Sensirion opens additional production building in Debrecen

Vetter Marks the Start of New Clinical Site Con­struction with Ground­breaking Ceremony - Vetter continues to expand in the US

Vetter Marks the Start of New Clinical Site Con­struction with Ground­breaking Ceremony - Vetter continues to expand in the US

A New Era Begins: BioSpring Builds High-Tech Manufacturing Facility for Pharmaceutical Nucleic Acid APIs

A New Era Begins: BioSpring Builds High-Tech Manufacturing Facility for Pharmaceutical Nucleic Acid APIs

GEA invests EUR 80 million in a pharmaceutical technology center for freeze-drying systems in Germany - First product chambers in the “Factory of the Future”

GEA invests EUR 80 million in a pharmaceutical technology center for freeze-drying systems in Germany - First product chambers in the “Factory of the Future”

PL BioScience Announces Major Site Expansion - New 1,200 m² facility in Aachen expands headquarters to support company growth and
scale Human Platelet Lysate production

PL BioScience Announces Major Site Expansion - New 1,200 m² facility in Aachen expands headquarters to support company growth and scale Human Platelet Lysate production

Stora Enso’s billion-euro investment in renewable packaging - Europe's most modern consumer board production line inaugurated in Finland

Stora Enso’s billion-euro investment in renewable packaging - Europe's most modern consumer board production line inaugurated in Finland

NextPharma announces the appointment of Ajeeth Enjeti as CEO to succeed Peter Burema

NextPharma announces the appointment of Ajeeth Enjeti as CEO to succeed Peter Burema

Dr. Roland Durner becomes new CEO of Bioengineering AG

Dr. Roland Durner becomes new CEO of Bioengineering AG